This analysis demonstrates that early day immunochemotherapy improves overall survival in lung cancer, suggesting timing matters.
The striking clinical relevance of the circadian immune system for patients with advanced lung cancer is supported by consistent overall survival prolongation through early time of day of immunochemotherapy, no matter the histological type.
No takes yet. Share an insight, caveat, or question.
F. LEVI (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: